rais po take share
execut front
rais po take share
stryker corp organ revenu growth guidanc
came well ahead expect strength across divis geographi
insid detail one busi truli stood except quarter
mako robot mako total knee procedur perform
sequenti also train record number surgeon
mako quarter bode well despit new competit
rais po ep vs ep previous
strong busi momentum ep estim move
reiter buy rate result suggest
zimmer rosa may face uphil battl view result
suggest us unlik report much growth
mako procedur applic
total surgeon train total knee
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
medic technolog compani
oper two busi segment orthoped
implant busi produc implant use joint
replac trauma spine craniomaxillofaci
surgic equip orthoped
hardwar well patient handl emerg
buy rate given top-tier
diversifi organ revenu growth outlook
balanc sheet capac believ one
best manag compani med-tech
syk hip knee busi continu strong momentum hip
grow global knee grow global despit tough comp knee
comp adj basi grew vs note us knee
comp adj growth acceler significantli vs comp
adj ou knee growth deceler significantli vs
trend seen hip comp adj ww hip growth similar
us hip comp adj acceler ou hip comp
adj growth deceler
tabl syk global hip knee growth similar comp adjust growth basi acceler us deceler ou
put comp adjust growth hip knee hip would deceler knee would come
constant currenc hip growth adjust sell day
constant currenc knee growth adjust sell day
repres estim assum growth comp adjust basi
y/i organ ex fx
y/i organ ex fx
y/i organ ex fx
price object assum trade ep estim
premium larg cap med-tech group premium believ justifi
given lead organ growth success track record also see
point ep upsid potenti well
upsid risk price object announc activ better
expect growth mako greater-than-expect impact share
loss consist strong earn growth given increasingli diversifi
downsid risk price object becom less confid execut
 econom impact surg busi lower capital-expenditure spend
wors anticip mako take market share expect
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
